TW202402285A - 神經鞘胺醇－１－磷酸受體促效劑的用途 - Google Patents
神經鞘胺醇－１－磷酸受體促效劑的用途 Download PDFInfo
- Publication number
- TW202402285A TW202402285A TW112135348A TW112135348A TW202402285A TW 202402285 A TW202402285 A TW 202402285A TW 112135348 A TW112135348 A TW 112135348A TW 112135348 A TW112135348 A TW 112135348A TW 202402285 A TW202402285 A TW 202402285A
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- alkyl
- hydrogen
- halogen
- atopic dermatitis
- Prior art date
Links
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 33
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- -1 C 1 -C 5 alkyl Inorganic materials 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Chemical group 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 229940071870 hydroiodic acid Drugs 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical group C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 2
- XKKXISSRVOVRGI-UHFFFAOYSA-N 1-[[1-chloro-6-[(3-chloro-1-propan-2-ylindazol-5-yl)methoxy]-3,4-dihydronaphthalen-2-yl]methyl]piperidine-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)N=C(Cl)C2=CC=1COC(C=C1CC2)=CC=C1C(Cl)=C2CN1CCC(C(O)=O)CC1 XKKXISSRVOVRGI-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 16
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 12
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 12
- 238000010171 animal model Methods 0.000 description 10
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108010035597 sphingosine kinase Proteins 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 102000036530 EDG receptors Human genes 0.000 description 2
- 108091007263 EDG receptors Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- ZZMYWYZPNZRYPX-SANMLTNESA-N (2r)-2-amino-2-[5-[4-[2-(4-phenylphenyl)ethoxy]-3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]propan-1-ol Chemical compound N1C([C@@](N)(CO)C)=NC=C1C(C=C1C(F)(F)F)=CC=C1OCCC1=CC=C(C=2C=CC=CC=2)C=C1 ZZMYWYZPNZRYPX-SANMLTNESA-N 0.000 description 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 description 1
- OKDGPOCKHMGDQY-UHFFFAOYSA-N 3,4-dihydropyrrol-2-one Chemical compound O=C1CCC=N1 OKDGPOCKHMGDQY-UHFFFAOYSA-N 0.000 description 1
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000703517 Dictyostelium discoideum Sphingosine-1-phosphate lyase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000000542 G Protein-Coupled Inwardly-Rectifying Potassium Channels Human genes 0.000 description 1
- 108010041667 G Protein-Coupled Inwardly-Rectifying Potassium Channels Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940087410 dexasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 229940069604 etrasimod Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 108010066791 sphingosine-1-phosphate phosphatase Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本揭露係關於式1之化合物或其藥學上可接受之鹽用於預防或治療異位性皮膚炎之用途：
其中，X、R1、R2、R3、R4、R5和R6與本文所定義的相同。
Description
本揭露係關於使用式1之化合物或其藥學上可接受之鹽於預防或治療異位性皮膚炎的用途：
其中，X、R1、R2、R3、R4、R5和R6與本文所定義的相同。
神經鞘胺醇-1-磷酸(S1P)係經由細胞內神經醯胺途徑所產生，其中，神經醯胺為起始材料。神經醯胺是經由兩種途徑所產生的，第一種是從頭生物合成途徑。神經醯胺亦為藉由細胞中的神經鞘磷脂(一種細胞膜成分)所降解產生者。各組織中的S1P量係藉由兩種生物合成神經鞘胺醇激酶(SphK)和兩種可生物降解的S1P磷酸酶(S1P裂解酶和溶血磷脂磷酸酶)所調控。已知藉由神經鞘胺醇激酶磷酸化神經鞘胺醇所產生的S1P調
合不同細胞反應，例如細胞增殖、細胞骨架組織和遷移、黏附-和緊密之聯結等合體(adhesive and tight junction assembly)以及形體生成。S1P以與包括白蛋白的血漿蛋白質的結合形式存在於血漿中為高量級(100至1,000nM)，然在組織中則為低量級。
S1P與S1P受體(G蛋白偶聯受體)結合以顯示不同生物學功能。作為S1P受體亞型，迄今為止已知的S1P1至S1P5分別命名為內皮分化基因(EDG)受體1、5、3、6和8。S1P受體已參與在不同地生物學功能，例如白血球再循環、神經細胞增殖、形體變化、遷移、內皮功能、血管調節(vasoregulation)和心血管發育。
近年來，許多研究發現，經由這些受體的S1P訊號傳導過程在與多發性硬化相關的包括炎症反應和修復過程之系列反應中具有著重要作用，且一種非選擇性S1P1促效劑實際上已批准作為多發性硬化症之治療劑。S1P受體係廣泛表現在與多發性硬化症誘導相關的許多細胞中。特別地，S1P1受體在免疫系統中具有主要作用。S1P1受體主要表達於淋巴細胞表面，例如T細胞和B細胞，且對S1P作出反應從而參與淋巴細胞的再循環。正常情況下，體液中的S1P濃度較高於在淋巴組織中者，且因此淋巴細胞藉由S1P濃度的差異離開淋巴組織，會在輸出淋巴循環後，於體液中循環。然而，如果淋巴細胞中的S1P1受體被S1P1促效劑下調，則淋巴細胞不會從淋巴組織流出，導致造成中樞神經系統(CNS)發炎和組織損傷之自體侵襲性(autoaggressive)淋巴細胞之浸潤減少。結果，獲得對多發性硬化症的治療效果。芬戈莫德(Fingolimod)為一種非選擇性S1P1促效劑，已被批准作為治療多發性硬化症的口服藥。當其與S1P1受體結合而激
活時，該受體反效果地從淋巴細胞表面降解或內化，從而發揮功能性的S1P1拮抗作用。
關於這種S1P受體，國際專利案第WO 2014/129796號(公開日期：2014年8月28日)揭露有效於作為S1P受體促效劑之化合物。
同時，異位性皮膚炎是一種慢性復發性皮膚濕疹疾病，雖然至今病因尚未明確，有聲稱係起因於外部抗原的作用而使免疫相關因素反應過度所致。用於異位性皮膚炎之藥物主要有免疫壓制劑、外用類固醇、抗組織胺劑等。然而，這些藥物的使用存在副作用或對異位性皮膚炎改善的侷限性。因此，持續需要能夠更有效地預防或治療異位性皮膚炎的新藥。
本揭露之一目的為提供下式1之化合物或其藥學上可接受之鹽在預防或治療異位性皮膚炎之用途：
其中，X、R1、R2、R3、R4、R5和R6與本文所定義的相同。
本揭露提供了一種用於預防或治療異位性皮膚炎之藥物，其包含治療有效量的下式1之化合物或其藥學上可接受之鹽：
其中，
X為碳或氮；
R1為氫或烷基；
R2為氫、烷基、鹵素、CN、CF3或COCF3；
R3和R4各自獨立地為氫、烷基、鹵素、鹵烷基或烷氧烷基；
R5為氫、烷基或鹵素；
R6為
；
R7為氫或烷基；和
m和n各自獨立地為0、1、2或3。
此外，本揭露提供用於預防或治療異位性皮膚炎之醫藥組成物，其包含治療有效量的式1之化合物或其藥學上可接受之鹽以及藥學上可接受之載體。
此外，本揭露提供了一種預防或治療異位性皮膚炎的方法，包含向有需要的個體給藥治療有效量的式1之化合物或其藥學上可接受之鹽。
此外，本揭露提供式1之化合物或其藥學上可接受之鹽用於預防或治療異位性皮膚炎的用途。
本揭露詳細地描述於下文。
根據本揭露的一方面，提供一種用於預防或治療異位性皮膚炎之藥物，其包含治療有效量的式1之化合物或其藥學上可接受之鹽。
根據本揭露的另一方面，提供一種用於預防或治療異位性皮膚炎之醫藥組成物，其包含治療有效量的式1之化合物或其藥學上可接受之鹽以及藥學上可接受之載體。
式1之化合物的製備方法在國際專利案第WO 2014/129796A1號中有詳細描述，該文獻以引用方式併入本文。
在根據本揭露的一實施例中，式1中
X為C或N；
R1為氫或C1-C5烷基；
R2為氫、C1-C5烷基、鹵素、CN、CF3或COCF3；
R3和R4各自獨立地為氫、C1-C5烷基、鹵素、鹵-C1-C5烷基或C1-C5烷氧基-C1-C5烷基；
R5為氫、C1-C5烷基或鹵素；
R6為
；
R7為氫或C1-C5烷基；以及
m和n各自獨立地為0、1、2或3。
在根據本揭露的另一個實施例中，式1之化合物是下式2之1-[1-氯-6-(3-氯-1-異丙基-1H-吲唑-5-基甲氧基)-3,4-二氫-萘-2-基甲基]-哌啶-4-羧酸：
在根據本揭露的另一實施例中，藥學上可接受之鹽包括，例如，酸加成鹽，其由含有藥學上可接受之陰離子的無毒酸加成鹽所形成，例如無機酸，如鹽酸、硫酸、硝酸、磷酸、氫溴酸、氫碘酸；有機酸，如酒石酸、甲酸、檸檬酸、乙酸、三氯乙酸、三氟乙酸、葡萄糖酸、苯甲酸、乳酸、富馬酸、馬來酸；或磺酸，如甲磺酸、苯磺酸、對甲苯磺酸或萘磺酸，但不限於此。
在根據本揭露的另一實施例中，個別個體的「治療有效量」是指足以實現上述藥理作用──即，如上所述的治療作用的量。化合物的量可根據個體的狀況和嚴重程度、給藥方式和待治療個體的年齡而變化，但可由所屬技術領域中具有通常知識者根據其知識來決定。
在根據本揭露的另一實施例中，根據給藥頻率和強度，式1之化合物的治療有效量通常在例如每天約0.1至500毫克之範圍。成人肌
內或靜脈內給藥的通常每日劑量在每天約0.1至300毫克之範圍，其可以分開的單位劑量給藥。一些患者需要更高的每日劑量。
在本揭露中，「醫藥組成物」除了本揭露的有效成分外，亦可包括其他成分，例如載體、稀釋劑、賦形劑等。因此，如有需要，醫藥組成物可包括藥學上可接受之載體、稀釋劑、賦形劑或其組合。該醫藥組成物有助於將化合物給藥至體內。化合物給藥的各種方法包括但不限於口服、注射、霧劑、腸胃外和局部給藥。
在本文中，「載體」是指促進化合物添加至細胞或組織中之化合物。例如，二甲基亞碸(DMSO)是一種一般載體，其有助於將許多有機化合物給藥至活細胞或組織中。
在本文中，「稀釋劑」是指不僅穩定生物活性形式且在溶劑中稀釋以溶解化合物之化合物。緩衝液中的溶解鹽為用作該領域之稀釋劑。一般使用的緩衝液是模擬體液中鹽形式之磷酸鹽緩衝鹽水。由於緩衝溶液可在低濃度調控溶液之pH值，緩衝稀釋劑難以改變化合物之生物活性。
在本文中，「藥學上可接受之」是指不損害化合物的生物活性和物理性質之性質。
本揭露的化合物可以配製為各種藥物給藥劑型。在本揭露之醫藥組成物的製備中，考慮到要製備的劑型，將活性成分──具體地，式1之化合物或其藥學上可接受之鹽──與選定的藥學上可接受之載體混合。例如，本揭露之醫藥組成物可根據需要配製為注射劑、口服製劑等。
本揭露之化合物可使用已知之藥物載體和賦形劑藉由一般方法配製，並插入至單元或複數個單元容器。製劑可為油或水性溶劑中的溶
液、懸浮液或乳液，並且包括一般分散劑、懸浮劑或穩定劑。此外，該化合物可為例如在使用前溶解於滅菌無熱原水中的乾粉形式。本揭露之化合物可藉由使用一般栓劑基質如可可脂或其他甘油酯配製成栓劑。用於口服給藥之固體形式包括膠囊、片劑、丸劑、粉劑和顆粒劑。較佳為膠囊劑和片劑。片劑和丸劑較佳為經腸衣被覆。固體形式是藉由將本揭露之化合物與至少一種載體混合製備而成，該載體選自惰性稀釋劑如蔗糖、乳糖或澱粉，潤滑劑如硬脂酸鎂、崩解劑、黏合劑等。此外，其可配製為經皮劑型──例如，作為洗劑、軟膏、凝膠、乳膏、貼劑或噴霧劑。
在本文中，術語「預防」是指減少或消除感染疾病的可能性。
在本文中，術語「治療」是用於意指阻止、延遲或改善表現出疾病症狀之個體的疾病進展。
本揭露之藥物或醫藥組成物可有效預防或治療異位性皮膚炎。
圖1為異位性皮膚炎動物模型之誘導過程示意圖。
圖2為在異位性皮膚炎動物模型中給藥測試物質後耳朵厚度減少之測量結果。
圖3為在異位性皮膚炎動物模型中給藥測試物質後耳朵重量減少之測量結果。
圖4為在異位性皮膚炎動物模型中給藥測試物質後IgE的血液量級降低之測量結果。
圖5為在異位性皮膚炎動物模型中給藥測試物質後表皮厚度減少之測量結果。
圖6為在異位性皮膚炎動物模型中給藥測試物質後肥大細胞蓄積減少之測量結果。
圖7為在異位性皮膚炎動物模型中與作為比較化合物的依曲莫德(etrasimod)進行比較的結果。
在下文中，藉由以下實例更詳細地解釋本揭露。然而，必須理解的是，本揭露的保護範圍並不限於實例。
製備例：1-[1-氯-6-(3-氯-1-異丙基-1H-吲唑-5-基甲氧基)-3,4-二氫-萘-2-基甲基]-哌啶-4-羧酸的之合成
根據國際專利案第WO2014/129796A1號之實例153中揭露之方法製備1-[1-氯-6-(3-氯-1-異丙基-1H-吲唑-5-基甲氧基)-3,4-二氫-萘-2-基甲基]-哌啶-4-羧酸(以下簡稱為「測試化合物」)。
實例1：異位性皮膚炎動物模型的誘導
藉由使用
唑啉酮(oxazolone)在小鼠(Balb/c)中誘導異位性皮膚炎之動物模型。將
唑啉酮的第一個致敏日設為第0天，從第7天開始每天一次口服或經皮給藥。當
唑啉酮的施用日期和藥物的給藥日期重疊時，在施用
唑啉酮約6小時後給藥藥物。
對於所有小鼠，在第一次施用
唑啉酮前一天去除腹毛。接著，藉由使用4：1比例之丙酮/玉米油製備1%或0.2%
唑啉酮，並以如表1和圖1所示之相同劑量和排程，對經刮除的小鼠腹部和雙耳進行致敏和誘導。
[表1]
實例2：用於口服給藥的物質之製備
如下表2所示，藉由使用0.5%甲基纖維素，為給藥劑量各自製備測試物質(測試化合物和地塞松(dexamethasone)作為陽性對照組)。至於測試化合物，其係考慮到HCl鹽形式來製備。將測試物質溶解於0.5%甲基纖維素中，接著進行超音波處理。如未完全溶解，則以懸浮液狀態給藥。
實例3：用於經皮(局部)給藥的物質之製備
將其以0.1%(w/v)之濃度溶解於溶液(PEG400：100%乙醇=1：1)中來製備測試物質藉。將5毫升PEG400加入至10毫克測試物質中並進行超音波處理。當其溶解到一定程度時，將5毫升100%乙醇加入並進行超音波處理以使其完全溶解。此外，每天製備及使用新鮮的媒劑和測試物質。
[表2]
實例4：測量結果
耳朵厚度的減小是在給藥測試物質後第14天和第21天測量，且結果示於表3和圖2。在給藥測試物質後第21天，於屍檢後測量耳朵重量的減少，且結果示於表3和圖3。在給藥測試物質後第21天，測量IgE血液量級的降低，且結果示於表3和圖4。此外，在給藥測試物質後第21天，測量耳朵組織表皮厚度和肥大細胞蓄積的減少，且結果示於表3、圖5和圖6。
[表3]
從表3和圖2至圖6可以看出，在
唑啉酮誘導的異位性皮膚炎動物模型中，與地塞松(陽性對照組)相比，測試化合物以劑量依賴性方式顯示出優異的效果。由這些結果證實，本揭露之化合物可用作預防或治療異位性皮膚炎之藥物。
實例5：對比實驗
為了與另一種S1P受體促效劑進行比較，依曲莫德(2-[(3R)-7-[[4-環戊基-3-(三氟甲基)苯基]甲氧基]-1,2,3,4-四氫環戊烷[b]吲哚-3-基]乙酸)，以與實例4相同之方式測量耳朵厚度的減少、耳朵重量的減少、IgE的血液量級、上皮厚度和肥大細胞蓄積，且結果示於表4和圖7中。
[表4]
從表4和圖7可以看出，與比較化合物依曲莫德相比，即使在較低劑量下，測試化合物也表現出相同或更好的效果。從這些結果可以預期，藉由給予相同劑量以獲得更好的療效或給予較低劑量以達到特定的療效量級，可以將全身暴露引起的副作用降至最低。此外，藉由對GIRKs(G蛋白偶聯內向整流鉀離子通道)的低親和力，可預期在副作用方面具有優勢，GIRKs可藉由S1P受體促效劑誘導心跳遲緩(brachycardia)。
Claims (8)
- 一種用於預防或治療異位性皮膚炎之藥物，包含治療有效量的下式1之化合物或其藥學上可接受之鹽：
其中，X為碳或氮；R1為氫或烷基；R2為氫、烷基、鹵素、CN、CF3或COCF3；R3和R4各自獨立地為氫、烷基、鹵素、鹵烷基或烷氧烷基；R5為氫、烷基或鹵素；R6為；
R7為氫或烷基；以及m和n各自獨立地為0、1、2或3。 - 如請求項1所述的用於預防或治療異位性皮膚炎之藥物，其中，X為C或N；R1為氫或C1-C5烷基；R2為氫、C1-C5烷基、鹵素、CN、CF3或COCF3；R3和R4各自獨立地為氫、C1-C5烷基、鹵素、鹵-C1-C5烷基或C1-C5烷氧基-C1-C5烷基；R5為氫、C1-C5烷基或鹵素；R6為；
R7為氫或C1-C5烷基；以及m和n各自獨立地為0、1、2或3。 - 如請求項1所述的用於預防或治療異位性皮膚炎之藥物，其中，式1之化合物為下式2之1-[1-氯-6-(3-氯-1-異丙基-1H-吲唑-5-基甲氧基)-3,4-二氫-萘-2-基甲基]-哌啶-4-羧酸：
- 如請求項1所述的用於預防或治療異位性皮膚炎之藥物，其中，該藥學上可接受之鹽選自由鹽酸、硫酸、硝酸、磷酸、氫溴酸、氫碘酸、酒石酸、甲酸、檸檬酸、乙酸、三氯乙酸、三氟乙酸、葡萄糖酸、苯甲酸、乳酸、富馬酸、馬來酸、甲磺酸、苯磺酸、對甲苯磺酸以及萘磺酸所組成之群組。
- 一種用於預防或治療異位性皮膚炎之醫藥組成物，包含治療有效量的下式1之化合物或其藥學上可接受之鹽，以及藥學上可接受之載體：
其中，X為碳或氮；R1為氫或烷基；R2為氫、烷基、鹵素、CN、CF3或COCF3；R3和R4各自獨立地為氫、烷基、鹵素、鹵烷基或烷氧烷基；R5為氫、烷基或鹵素；R6為；
R7為氫或烷基；以及m和n各自獨立地為0、1、2或3。 - 如請求項5所述的用於預防或治療異位性皮膚炎之醫藥組成物，其中，X為C或N；R1為氫或C1-C5烷基；R2為氫、C1-C5烷基、鹵素、CN、CF3或COCF3；R3和R4各自獨立地為氫、C1-C5烷基、鹵素、鹵-C1-C5烷基或C1-C5烷氧基-C1-C5烷基；R5為氫、C1-C5烷基或鹵素；R6為；
R7為氫或C1-C5烷基；以及m和n各自獨立地為0、1、2或3。 - 如請求項5所述的用於預防或治療異位性皮膚炎之醫藥組成物，其中，式1之化合物為下式2之1-[1-氯-6-(3-氯-1-異丙基-1H-吲唑-5-基甲氧基)-3,4-二氫-萘-2-基甲基]-哌啶-4-羧酸：
- 如請求項5所述的用於預防或治療異位性皮膚炎之醫藥組成物，其中，該藥學上可接受之鹽選自由鹽酸、硫酸、硝酸、磷酸、氫溴酸、氫碘酸、酒石酸、甲酸、檸檬酸、乙酸、三氯乙酸、三氟乙酸、葡萄糖酸、苯甲酸、乳酸、富馬酸、馬來酸、甲磺酸、苯磺酸、對甲苯磺酸以及萘磺酸所組成之群組。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0125583 | 2020-09-28 | ||
| KR20200125583 | 2020-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202402285A true TW202402285A (zh) | 2024-01-16 |
Family
ID=80846731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110135832A TW202222314A (zh) | 2020-09-28 | 2021-09-27 | 神經鞘胺醇－１－磷酸受體促效劑的用途 |
| TW112135348A TW202402285A (zh) | 2020-09-28 | 2021-09-27 | 神經鞘胺醇－１－磷酸受體促效劑的用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110135832A TW202222314A (zh) | 2020-09-28 | 2021-09-27 | 神經鞘胺醇－１－磷酸受體促效劑的用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230330077A1 (zh) |
| EP (1) | EP4212159A4 (zh) |
| JP (1) | JP2023542730A (zh) |
| KR (1) | KR102703801B1 (zh) |
| CN (1) | CN116437921A (zh) |
| AU (1) | AU2021349680B2 (zh) |
| BR (1) | BR112023005536A2 (zh) |
| CA (1) | CA3192701A1 (zh) |
| MX (1) | MX2023003567A (zh) |
| TW (2) | TW202222314A (zh) |
| WO (1) | WO2022065939A1 (zh) |
| ZA (1) | ZA202304537B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4324827A4 (en) * | 2021-04-14 | 2024-08-21 | Lg Chemical Ltd | PHARMACEUTICALLY ACCEPTABLE SALT OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST AND CRYSTALLINE FORM THEREOF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ599914A (en) * | 2009-11-13 | 2014-08-29 | Receptos Inc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| DK2958913T3 (en) * | 2013-02-20 | 2018-11-05 | Lg Chemical Ltd | SPHINGOSIN-1 PHOSPHATRECEPTOR AGONISTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS AN ACTIVE AGENT |
| EP4445956A2 (en) * | 2015-01-06 | 2024-10-16 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
-
2021
- 2021-09-27 CN CN202180065509.2A patent/CN116437921A/zh active Pending
- 2021-09-27 WO PCT/KR2021/013097 patent/WO2022065939A1/ko active Application Filing
- 2021-09-27 US US18/028,618 patent/US20230330077A1/en active Pending
- 2021-09-27 AU AU2021349680A patent/AU2021349680B2/en active Active
- 2021-09-27 JP JP2023519550A patent/JP2023542730A/ja active Pending
- 2021-09-27 BR BR112023005536A patent/BR112023005536A2/pt unknown
- 2021-09-27 TW TW110135832A patent/TW202222314A/zh unknown
- 2021-09-27 KR KR1020210127111A patent/KR102703801B1/ko active IP Right Grant
- 2021-09-27 TW TW112135348A patent/TW202402285A/zh unknown
- 2021-09-27 MX MX2023003567A patent/MX2023003567A/es unknown
- 2021-09-27 CA CA3192701A patent/CA3192701A1/en active Pending
- 2021-09-27 EP EP21872967.1A patent/EP4212159A4/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04537A patent/ZA202304537B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023005536A2 (pt) | 2023-04-25 |
| US20230330077A1 (en) | 2023-10-19 |
| CN116437921A (zh) | 2023-07-14 |
| CA3192701A1 (en) | 2022-03-31 |
| MX2023003567A (es) | 2023-04-04 |
| JP2023542730A (ja) | 2023-10-11 |
| ZA202304537B (en) | 2024-07-31 |
| KR102703801B1 (ko) | 2024-09-05 |
| EP4212159A1 (en) | 2023-07-19 |
| AU2021349680A1 (en) | 2023-06-08 |
| KR20220043046A (ko) | 2022-04-05 |
| EP4212159A4 (en) | 2024-03-06 |
| AU2021349680B2 (en) | 2024-09-12 |
| TW202222314A (zh) | 2022-06-16 |
| WO2022065939A1 (ko) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3060200B1 (en) | Tyrosine derivatives and compositions comprising them | |
| US20190216806A1 (en) | Novel uses | |
| MXPA04011547A (es) | Nuevos metodos y composiciones para aliviar el dolor. | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| US20100222376A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| IL269789A (en) | Treatment of adipocytes | |
| TW202402285A (zh) | 神經鞘胺醇－１－磷酸受體促效劑的用途 | |
| JP2014530835A (ja) | Ｓ１ｐ受容体モジュレーターまたはｓ１ｐ受容体アゴニストのための投薬量レジメン | |
| US20220193075A1 (en) | Therapeutic drug for dyskinesia | |
| EP1491211A1 (en) | Remedy for glioblastoma | |
| JP2023030112A (ja) | 肥満細胞疾患の処置のための方法及び医薬組成物 | |
| JP4362457B2 (ja) | 神経因性疼痛治療剤 | |
| TW202220651A (zh) | 神經鞘胺醇－１－磷酸受體促效劑的用途 | |
| US11559525B2 (en) | Therapeutic drug for dyskinesia | |
| AU2017342240A1 (en) | Methods for treating ocular disease using inhibitors of CSF-1R | |
| JP4741131B2 (ja) | 低血圧およびショックの治療または予防 | |
| JP4227121B2 (ja) | 神経因性疼痛治療剤 | |
| CA3223692A1 (en) | Erk1/2 inhibitor combination therapy | |
| US20240180874A1 (en) | Improved treatment of ovarian cancer with nirogacestat |